Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Microbiol Infect Dis ; 32(11): 1423-6, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23686458

RESUMO

The aim of this study was to examine the incidence and antibiotic sensitivity of Ureaplasma urealyticum and Mycoplasma hominis strains cultured from the genital discharges of sexually active individuals who attended our STD outpatient service. Samples were taken with universal swab (Biolab®, Budapest, Hungary) into the Urea-Myco DUO kit (Bio-Rad®, Budapest, Hungary) and incubated in ambient air for 48 h at 37 °C. The determination of antibiotic sensitivity was performed in U9 and arginin broth using the SIR Mycoplasma kit (Bio-Rad®, Budapest, Hungary) under the same conditions. Between 01.05.2008 and 31.12.2011, 373/4,466 (8.35 %) genito-urethral samples with U. urealyticum and 41/4,466 (0.91 %) genito-urethral samples with M. hominis infection were diagnosed in sexually active individuals in the National STD Center, Semmelweis University. U. urealyticum was isolated in 12.54 % in the cervix and 4.1 % in the male urethra, while M. hominis was isolated in 1.33 % in the cervix and 0.51 % in the male urethra. The affected age group was between 21 and 60 years old. U. urealyticum strains were sensitive to tetracycline (95.9 %), doxycycline (97.32 %), and azithromycin (85.79 %), and resistant to erythromycin (81.23 %), clindamycin (75.06 %), and ofloxacin (25.2 %). Cross-resistance occurred in 38.71 % of patients to erythromycin and clindamycin. M. hominis strains were sensitive to clindamycin, ofloxacin, and doxycycline in more than 95 %, to tetracycline in 82.92 %, and no cross-resistance was detected among the antibiotics. Our study confirms that the continuously changing antibiotic resistance of ureaplasmas and mycoplasmas should be followed at least in a few centers in every country, so as to determine the best local therapy options for sexually transmitted infection (STI) patients.


Assuntos
Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/microbiologia , Mycoplasma hominis/efeitos dos fármacos , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/microbiologia , Ureaplasma urealyticum/efeitos dos fármacos , Adulto , Antibacterianos/farmacologia , Farmacorresistência Bacteriana , Feminino , Genitália/microbiologia , Humanos , Hungria/epidemiologia , Incidência , Masculino , Testes de Sensibilidade Microbiana , Mycoplasma hominis/isolamento & purificação , Ureaplasma urealyticum/isolamento & purificação
2.
Eur J Microbiol Immunol (Bp) ; 2(2): 157-60, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24672684

RESUMO

From January 1, 2009 through December 31, 2011, from 33,753 blood samples for syphilis screening, Treponema pallidum infections were confirmed in 241 pregnant women at the Department of Dermatology, Venerology, and Dermatooncology of Semmelweis University Budapest. In this period, four children born to inadequately or untreated women were confirmed to have connatal syphilis. The height of rapid plasma reagin (RPR) titer was measured to determine the stage of the infection and to examine the success of the antilues therapy. The diagnosis of maternal syphilis infection was confirmed with enzyme linked immunosorbent assay (ELISA), T. pallidum particle agglutination (TPPA), and IgG and IgM immunoblots. Maternal IgM immunoblot results identify mothers at risk of delivering babies with connatal syphilis better than the height of maternal RPR titer. The standard serological tests are less useful in newborns because of IgG transfer across the placenta. IgM test which depends on the infant's response has more specificity in diagnosing connatal syphilis.

3.
Curr Med Chem ; 16(30): 3996-4002, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19747127

RESUMO

Antimicrobial resistance is an emerging worldwide concern in light of the widespread antimicrobial drug use in humans, livestock and companion animals. The treatment of life-threatening infections is especially problematic because clinical strains rapidly acquire multiple-drug resistance. Antimicrobial peptides have long been considered to be viable alternatives to small molecule antibiotics. However, the peptides' parenteral use is frequently hampered by inadequate safety margins and rapid renal clearance leaving them suitable only for topical applications. The proline-rich peptide A3-APO represents a family of a new class of synthetic dimers that kill bacteria by a dual mode of action and carry domains for interaction with both the bacterial membrane and an intracellular target. From a series of designer antibacterial peptides, A3-APO emerged as a viable preclinical candidate by virtue of its superior ability to disintegrate the bacterial membrane, inhibit the 70-kDa heat shock protein DnaK alone or in synergy with small molecule antibiotics, lack of eukaryotic toxicity and withstand proteolytic degradation in body fluids. As many other proline-rich peptides, A3-APO binds to the C-terminal helical lid of bacterial DnaK and inhibits chaperone-assisted protein folding in bacteria but not in mammalian Hsp70. In this review, the structure, pharmacokinetic properties, antimicrobial spectrum of peptide A3-APO and its in vivo metabolite are summarized and the in vitro and in vivo antimicrobial effects (antimicrobial susceptibilities, postantibiotic effects, resistance induction) are discussed in detail.


Assuntos
Antibacterianos/química , Antibacterianos/farmacologia , Peptídeos/química , Peptídeos/farmacologia , Sequência de Aminoácidos , Animais , Desenho de Fármacos , Testes de Sensibilidade Microbiana , Modelos Moleculares , Dados de Sequência Molecular , Prolina/química , Prolina/farmacologia
4.
Acta Microbiol Immunol Hung ; 48(3-4): 359-91, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11791339

RESUMO

Molecular mechanisms of the action of beta-lactam and glycopeptide antibiotics, as well as genetic background and phenotypical features of the resistance of staphylococci, streptococci and enterococci to these antibiotics are reviewed. Furthermore, susceptibility patterns concerning beta-lactam and glycopeptide drugs of staphylococcal, streptococcal, as well as enterococcal strains isolated from clinical specimens at the Semmelweis University of Medicine, Budapest, Hungary between January 1997 and December 2000 are also presented.


Assuntos
Antibacterianos/farmacologia , Glicopeptídeos , Staphylococcus/efeitos dos fármacos , Streptococcus/efeitos dos fármacos , Farmacorresistência Bacteriana/genética , Farmacorresistência Bacteriana/fisiologia , Enterococcus/efeitos dos fármacos , Enterococcus/genética , Fenótipo , Staphylococcus/enzimologia , Staphylococcus/genética , Streptococcus/enzimologia , Streptococcus/genética , beta-Lactamases/genética , beta-Lactamas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA